tiprankstipranks
Trending News
More News >
Stevanato Group (STVN)
NYSE:STVN
US Market
Advertisement

Stevanato Group (STVN) Earnings Dates, Call Summary & Reports

Compare
125 Followers

Earnings Data

Report Date
Nov 11, 2025
Before Open (Confirmed)
Period Ending
2025 (Q3)
Consensus EPS Forecast
0.15
Last Year’s EPS
0.14
Same Quarter Last Year
Moderate Buy
Based on 5 Analysts Ratings

Earnings Call Summary

Q1 2025
Earnings Call Date:May 08, 2025|
% Change Since:
|
Earnings Call Sentiment|Positive
The earnings call reflected a positive sentiment with strong revenue growth, particularly in high-value solutions, and improvements in profit margins. The company showed resilience in dealing with challenges in the Engineering segment and tariff impacts, and expressed confidence in its long-term growth trajectory.
Company Guidance
During the first quarter of fiscal 2025, Stevanato Group reported strong performance, highlighted by a 9% increase in revenue to EUR 256.6 million, driven by an 11% growth in the Biopharmaceutical and Diagnostics Solutions (BDS) segment. High-value solutions, including a modest recovery in EZ-fill vials, accounted for 43% of total revenue. The company's gross profit margin improved by 80 basis points to 27.2%, while operating profit margin rose by 280 basis points to 13.5%. Adjusted EBITDA increased by 100 basis points to 22.4%. Despite a 4% revenue decline in the Engineering segment due to legacy projects in Denmark, the company remains on track to complete these projects in 2025. Looking forward, Stevanato anticipates mid- to high single-digit growth in the BDS segment and neutral to low single-digit growth in the Engineering segment, with continued strong demand for high-value solutions. The company's updated guidance includes anticipated tariff-related impacts of approximately EUR 4.5 million to operating profit, with ongoing mitigation efforts expected to further reduce exposure.
Revenue Growth and Strong Start to Fiscal 2025
The company reported a 9% revenue growth in the first quarter of 2025, reaching EUR 256.6 million, with a strong performance in the Biopharmaceutical and Diagnostics Solutions (BDS) Segment, which grew by 11%.
High-Value Solutions Growth
Revenue from high-value solutions grew 25% to EUR 110.3 million, accounting for 43% of total revenue, driven by strong demand for high-value syringes and stabilization in vial demand.
Improvement in Gross and Operating Profit Margins
Consolidated gross profit margin increased by 80 basis points to 27.2%, and the operating profit margin increased by 280 basis points to 13.5% due to strong performance in the BDS segment and cost-curtailing initiatives.
Positive Order Intake for Vials
Double-digit growth in order intake for both bulk and sterile vials, indicating a recovery in the vial market.
Progress in Capital Investment Projects
Significant progress in the Fishers and Latina facilities, with scaling of commercial syringe production and manufacturing line installations, supporting strong market demand.

Stevanato Group (STVN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

STVN Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Nov 11, 2025
2025 (Q3)
0.15 / -
0.14
Aug 05, 2025
2025 (Q2)
0.13 / 0.13
0.10522.22% (+0.02)
May 08, 2025
2025 (Q1)
0.10 / 0.12
0.09325.00% (+0.02)
Mar 06, 2025
2024 (Q4)
0.21 / 0.22
0.215.56% (+0.01)
Nov 05, 2024
2024 (Q3)
0.15 / 0.14
0.175-20.00% (-0.03)
Aug 06, 2024
2024 (Q2)
0.11 / 0.10
0.163-35.71% (-0.06)
May 09, 2024
2024 (Q1)
0.13 / 0.09
0.128-27.27% (-0.03)
Mar 07, 2024
2023 (Q4)
0.22 / 0.21
0.221-5.26% (-0.01)
Oct 31, 2023
2023 (Q3)
0.18 / 0.17
0.1637.14% (+0.01)
Jul 28, 2023
2023 (Q2)
0.15 / 0.16
0.1416.67% (+0.02)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

STVN Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Aug 05, 2025
$25.58$23.09-9.73%
May 08, 2025
$21.74$22.42+3.13%
Mar 06, 2025
$19.01$20.64+8.57%
Nov 05, 2024
$19.33$22.44+16.09%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Stevanato Group (STVN) report earnings?
Stevanato Group (STVN) is schdueled to report earning on Nov 11, 2025, Before Open (Confirmed).
    What is Stevanato Group (STVN) earnings time?
    Stevanato Group (STVN) earnings time is at Nov 11, 2025, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is STVN EPS forecast?
          STVN EPS forecast for the fiscal quarter 2025 (Q3) is 0.15.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis